Joanna-horobin

Biography

Ms Horobin has comprehensive experience within the biopharmaceutical industry. She is currently senior vice president, chief medical officer and a member of the leadership team at Idera Pharmaceuticals Inc. in Cambridge, MA, USA. Ms Horobin's current role includes the development and regulatory strategy as well as the execution of the clinical trial programme for the company's pipeline of novel oligonucleotides for the treatment of rare oncology and other indications. Prior to this position, she was chief medical officer of Verastem Inc., and chief executive officer of Syndax Pharmaceuticals. Additionally, Ms Horobin has held several roles of increasing responsibility at global pharmaceutical companies such as Rhône-Poulenc Rorer (now Sanofi) where she led the global launch of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (lenogratism) for colorectal cancer, and played significant leadership roles in the approvals of several successful products. Ms Horobin has served as a director in the company since October 2016. She is an independent director of the board. Ms Horobin has comprehensive experience within the biopharmaceutical industry. She is currently senior vice president, chief medical officer and a member of the leadership team at Idera Pharmaceuticals Inc. in Cambridge, MA, USA. Ms Horobin's current role includes the development and regulatory strategy as well as the execution of the clinical trial programme for the company's pipeline of novel oligonucleotides for the treatment of rare oncology and other indications. Prior to this position, she was chief medical officer of Verastem Inc., and chief executive officer of Syndax Pharmaceuticals. Additionally, Ms Horobin has held several roles of increasing responsibility at global pharmaceutical companies such as Rhône-Poulenc Rorer (now Sanofi) where she led the global launch of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (lenogratism) for colorectal cancer, and played significant leadership roles in the approvals of several successful products. Ms Horobin has served as a director in the company since October 2016. She is an independent director of the board.

Research Interest

Business Management